TY - JOUR
T1 - Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
AU - Ghobrial, Irene M.
AU - Gormley, Nicole
AU - Kumar, Shaji K.
AU - Mateos, Maria Victoria
AU - Bergsagel, P. Leif
AU - Chesi, Marta
AU - Dhodapkar, Madhav V.
AU - Dispenzieri, Angela
AU - Fonseca, Rafael
AU - Getz, Gad
AU - Kastritis, Efstathios
AU - Kristinsson, Sigurdur Y.
AU - Martinez-Climent, Jose Angel
AU - Manier, Salomon
AU - Marinac, Catherine R.
AU - Maura, Francesco
AU - Morgan, Gareth J.
AU - Davies, Faith E.
AU - Nadeem, Omar
AU - Nuvolone, Mario
AU - Paiva, Bruno
AU - O’Donnell, Elizabeth
AU - Prosper, Felipe
AU - Shah, Urvi A.
AU - Sklavenitis-Pistofidis, Romanos
AU - Sperling, Adam S.
AU - Vassiliou, George S.
AU - Munshi, Nikhil C.
AU - Castle, Philip E.
AU - Anderson, Kenneth C.
AU - San Miguel, Jesus F.
N1 - Publisher Copyright:
©2024 American Association for Cancer Research.
PY - 2024/5/1
Y1 - 2024/5/1
N2 - While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
AB - While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
UR - http://www.scopus.com/inward/record.url?scp=85192028835&partnerID=8YFLogxK
U2 - 10.1158/2643-3230.bcd-24-0022
DO - 10.1158/2643-3230.bcd-24-0022
M3 - Article
C2 - 38441243
AN - SCOPUS:85192028835
SN - 2643-3230
VL - 5
SP - 146
EP - 152
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 3
ER -